Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 3/20 | 0.48 |
| ▸ | KMO | O15229 | 1/20 | 0.44 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.42 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.41 |
| ▸ | KDM4A | O75164 | 1/20 | 0.40 |
| ▸ | KDM5A | P29375 | 1/20 | 0.40 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.40 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13123328 | 0.91 | XDH (0.49) | XDHKMOIKBKETBK1KDM4C | |
| SCHEMBL3451490 | 0.90 | XDH (0.48) | XDHKMOIKBKETBK1KDM4C | |
| SCHEMBL3452416 | 0.89 | XDH (0.50) | XDHKMOIKBKETBK1KDM4C | |
| SCHEMBL1331087 | 0.87 | XDH (0.51) | XDHKMOTBK1KDM4CKDM5A | |
| SCHEMBL1330399 | 0.87 | XDH (0.51) | XDHKMOTBK1KDM4CKDM5A | |
| SCHEMBL3451829 | 0.87 | XDH (0.51) | XDHKMOTBK1KDM4CKDM5A | |
| Hydrochloric Acid SCHEMBL1331923 | 0.86 | XDH (0.50) | XDHKMOTBK1KDM4CKDM5A | |
| SCHEMBL14383589 | 0.84 | XDH (0.48) | XDHKMOKDM4CKDM4A | |
| SCHEMBL13123869 | 0.82 | KDM4E (0.40) | XDHTBK1 | |
| SCHEMBL1331290 | 0.79 | XDH (0.52) | XDHKMOKDM4CKDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1783116-B1 | 2-PHENYLPYRIDINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2009-08-26 | — | — | EP | disclosed |
| US-20070275950-A1 | 2-Phenylpyridine Derivative | ASTELLAS PHARMA INC. (JP) | 2007-11-29 | — | — | US | disclosed |
| EP-1783116-A1 | 2-PHENYLPYRIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2007-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275950-A1 | 2-Phenylpyridine Derivative | NLRP3, XDH, UACA | XDH 2/4885KMO 620/4885IKBKE 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.